James Crowe Jr.

Monoclonal antibodies against Marburg virus — a more lethal cousin of the RNA virus that causes COVID-19 — may aid in the development of antibody "cocktails" to counter viral infection. Read More

A research team led by scientists at Vanderbilt University Medical Center has developed an antibody mixture that in animals is highly effective in blocking infection by the Ebola virus. Read More

VUMC scientists are redoubling their efforts to help people fight off bird flu. Their focus is H7N9, one of the most dangerous of the influenza viruses that have been transmitted from birds to humans. Read More

Researchers at Vanderbilt University Medical Center are partnering with the Dutch biopharmaceutical firm Batavia Biosciences and Nashville-based IDBiologics to bring to the clinic a highly potent Zika virus neutralizing antibody they isolated three years ago. Read More

James Crowe Jr., MD, director of the Vanderbilt Vaccine Center, will be honored today by the science and technology company Merck KGaA, Darmstadt, Germany for his contributions to developing new therapeutics and vaccines against some of the world’s deadliest viruses. Read More

Scientists are testing a new way to fight chikungunya virus that involves injecting genetic material into the bodies of infected and at-risk individuals to trigger rapid production of potent, virus-neutralizing antibodies. Read More

The discovery of these antibodies could significantly improve the diagnosis and treatment of the leading cause of stomach illness in the world. Read More

The computer-aided design and engineering of antibodies and vaccine candidates that can neutralize viral scourges like influenza and Ebola will be the topic of an Aug. 17 poster session presented by the Vanderbilt Center for Structural Biology and the Vanderbilt Vaccine Center. Read More

Researchers led by James Crowe Jr. are a step closer to developing a broadly effective antibody treatment against the three major Ebola viruses that cause lethal disease in humans. The hope is that the antibodies — like heat-seeking missiles — would seek out and destroy the viruses before they can wreak havoc in the body. Read More

A new Vanderbilt study suggests it may be possible to develop antibody therapies or a universal vaccine effective against multiple Ebola virus family members. Read More

Targeting the protein that mosquito-borne viruses use to enter cells could be a strategy for preventing infection by multiple emerging viruses. Read More

Few people die from rabid animal bites in the United States thanks to the near-universal availability of human rabies immune globulin and rabies vaccine, which are given as separate shots as soon as possible after exposure to the rabies virus. Read More

The laboratory of James Crowe Jr., MD, director of the Vanderbilt Vaccine Center, received the 2018 Vaccine Industry Excellence Award for Best Academic Research Team at the 18th World Vaccine Congress in Washington, DC, this week. Read More

Newly discovered features in an RSV protein may be useful for rational structure-based vaccine design. Read More

The U.S. Defense Advanced Research Projects Agency (DARPA) has signed a five-year cooperative agreement worth up to $28 million with Vanderbilt University Medical Center (VUMC) to develop methods for preventing the global spread of viruses like chikungunya and Zika. Read More

James Crowe Jr., MD, director of the Vanderbilt Vaccine Center at Vanderbilt University Medical Center (VUMC), has been named a fellow of the National Academy of Inventors (NAI). Read More

Researchers at Vanderbilt University Medical Center are leading an international effort to develop a universal influenza vaccine that would protect everyone against all strains of the flu anywhere in the world. Read More

The Human Vaccines Project and Vanderbilt University Medical Center (VUMC) announced this week that they joined forces with Illumina Inc. to decipher the human immunome, the genetic underpinnings of the immune system. Read More

James Crowe Jr., M.D., director of the Vanderbilt Vaccine Center, is the 2017-2018 recipient of the Samuel Rosenthal Prize for Excellence in Academic Pediatrics. Read More

Researchers at Vanderbilt University Medical Center (VUMC) have taken another step toward developing a vaccine against respiratory syncytial virus (RSV), the major cause of life-threatening pneumonia in infants worldwide. Read More